00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
00:26 , Jan 25, 2019 |  BC Week In Review  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Jan. 23 in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia...
23:35 , Jan 23, 2019 |  BC Extra  |  Financial News

BridgeBio raises $299M to advance rare disease portfolio

BridgeBio Pharma LLC (Palo Alto, Calif.) said it raised $299.2 million on Wednesday in a venture round to develop compounds for rare genetic diseases. The company in-licenses preclinical and clinical stage assets from academia and...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
04:43 , Nov 30, 2018 |  BC Week In Review  |  Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

Dermatology company Leo Pharma A/S (Ballerup, Denmark) gained an option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib to treat rare skin cancer Gorlin syndrome. PellePharm will receive...
11:06 , Nov 20, 2018 |  BC Extra  |  Company News

Leo Pharma invests in PellePharm to develop rare skin disease therapy

Dermatology company Leo Pharma A/S (Ballerup, Denmark) gained an option to acquire PellePharm Inc. (Menlo Park, Calif.) and will help fund development of PellePharm's patidegib to treat rare skin cancer Gorlin syndrome. PellePharm will receive...
20:44 , Nov 6, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology In vitro , cell culture and mouse studies identified a PANK3 activator that could help treat pantothenate kinase-associated neurodegeneration (PKAN), which is caused by PANK2 deficiency and leads to low Coenzyme A levels...
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
18:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Novartis' infigratinib leads to 25.4% ORR in urothelial carcinoma patients

Data from 67 patients with previously treated advanced urothelial carcinoma with fibroblast growth factor (FGF) receptor 3 (FGFR3; CD333) alterations in an expansion cohort of an open-label, international Phase I trial showed that once-daily 125...
21:43 , Jul 12, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2018

New Therapeutic Targets and Biomarkers: June 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2018. Therapeutic targets are defined as any protein, gene or other...